CURIS INC CRIS Cash Flow

Curis inc (CRIS)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows from Operating Activities:
Cash flows from operating activities:
Net loss
-31,957	-32,141	-29,474	-30,261	-31,712	-32,575	-34,662	-42,896	-48,322	-53,317	-56,623	-69,512	-66,711	-60,411	-62,538	-39,735	-36,574	-58,981	-51,209	-51,246	-45,013	-18,729	-17,237	-13,525	-12,923	-12,322	-20,495	-22,012	-23,604	-16,416	2,016	1,194	-833	-9,858	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
115	125	158	168	182	200	163	186	198	200	228	216	214	193	179	169	153	161	163	162	159	155	151	148	144	141	139	133	130	126	122	122	116	107	0	0	0
Non-cash lease expense
865	956	673	448	240	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expense
2,632	2,658	2,597	2,807	3,365	3,940	4,688	5,086	5,482	5,359	4,994	5,333	4,656	4,325	4,311	3,581	3,695	3,875	3,689	3,606	3,267	3,060	2,748	2,852	3,085	3,002	3,284	3,170	3,261	3,623	3,258	2,762	2,117	1,772	0	0	0
Issuance of common stock in consideration for rights granted under the Aurigene collaboration agreement (see Note 3(b))
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23,968	0	0	0	-	-	-	-	-	-	-	-	964	0	0	0	-	-	-	-
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-717	-1,926	-785	-561	-771	0	0	0	-	-	-	-	-	-	-	-
Amortization of debt issuance costs
0	8	18	27	34	35	34	32	34	144	147	152	155	48	48	49	49	56	64	67	81	89	94	104	104	104	0	0	0	-	-	-	-	-	-	-	-
Non-cash imputed interest expense related to the sale of future royalties
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash imputed interest expense related to the sale of future royalties
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on disposal of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Non-cash interest expense on investments
43	64	67	67	62	147	153	132	124	53	-54	-110	-174	-168	-113	-205	-439	-149	-180	-53	90	-170	-42	-0	148	-95	47	171	177	434	278	-26	-84	-246	0	0	0
Gain (Loss) on Extinguishment of Debt
0	-3,495	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense on operating lease liability
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of fixed assets
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment-in kind interest on Curis Royalty's debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash in-kind interest accrued on Curis Royalty's debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Loss on disposal of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	77	0	0	0
Changes in operating assets and liabilities:
Accounts receivable
721	380	42	-371	-705	-209	399	274	296	614	599	362	449	353	-461	-224	-23	145	478	-2,750	400	484	682	3,980	604	569	232	544	424	865	786	218	257	-50	0	0	0
Prepaid expenses, and other assets
631	237	498	43	-228	-162	-31	-181	-134	-267	-278	-18	115	85	652	256	146	726	172	407	331	2	158	-50	103	116	374	86	43	-40	-596	-94	-51	-24	0	0	0
Accounts payable and accrued and other liabilities
2,266	60	-1,966	-3,778	-3,682	-1,873	-2,367	-3,106	-314	-376	1,284	4,717	1,117	2,315	2,807	1,582	2,265	1,774	91	-188	78	361	90	443	465	181	286	427	-417	20	491	260	558	416	0	0	0
Operating lease liability
-920	-1,001	-749	-498	-247	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total adjustments
3,978	5,936	3,928	4,374	4,378	2,510	2,032	2,008	5,149	4,962	6,386	28,173	23,741	24,600	25,251	5,548	6,455	29,090	27,488	29,923	25,746	1,916	-395	-1,745	2,406	2,782	3,129	189	146	1,223	4,817	5,394	4,835	5,295	0	0	0
Net cash used in operating activities
-27,967	-26,200	-25,540	-25,887	-27,334	-30,065	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,833	6,588	4,002	-4,563	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0	-	-17,633	-15,270	-10,517	-9,539	0	0	0	-	-	-	-	-	-	-	-
Cash flows from investing activities:
Cash flows from investing activities:
Purchases of investments
-	-	-	-	-	26,741	32,975	44,577	55,311	51,121	51,445	36,371	40,728	57,639	78,130	105,688	95,145	123,240	98,709	82,347	85,572	41,399	60,203	63,471	69,127	65,827	69,106	66,694	57,499	69,153	53,856	46,689	45,014	42,136	0	0	0
Sales and maturities of investments
11,532	7,050	10,200	15,750	33,750	48,200	47,250	59,121	50,103	47,679	64,655	64,864	80,534	88,092	110,117	120,215	120,023	116,822	81,916	63,455	57,915	57,749	65,363	61,988	57,793	52,349	49,861	52,060	43,520	46,214	36,532	39,987	39,927	51,834	0	0	0
Decrease in restricted cash/investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14	-14	-14	-14	-14	-13	-13	-13	-13	-13	-13	-13	-41	-41	-83	-83	-261	0	0	0
Purchase of property and equipment
282	41	41	49	8	85	126	139	213	188	207	199	373	329	269	289	41	48	0	0	0	-	-	-	-	153	197	106	129	104	53	47	231	260	0	0	0
Proceeds from sale of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	77	0	0	0
Net cash provided by investing activities
-215	-4,456	-1,351	1,875	23,747	21,374	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17,317	-6,625	-5,189	9,775	0	0	0
Net cash (used in)/provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0	-	5,091	-1,645	-11,438	-13,617	0	0	0	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Cash flows from financing activities:
Sale of common stock
0	-	-	-	0	-	-	-	-	41,546	41,809	6,214	6,214	0	1	1	-239	64,620	0	0	0	-	-	-	-	16,245	3,654	3,745	2,127	5,105	5,415	5,046	4,465	1,792	0	0	0
Proceeds from royalty interest purchase agreement with Oberland Capital Management, LLC
0	65,000	65,000	65,000	65,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of issuance costs on royalty interest purchase agreement
334	584	584	584	250	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock under the Company’s stock-based compensation plans
-	-	-	-	-	-	-	-	-	1,138	2,766	3,099	3,301	2,907	2,164	1,709	1,147	1,206	229	221	231	283	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment of liability of future royalties, net of imputed interest
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from new credit agreement with HealthCare Royalty
-	-	-	-	-	-	-	-	-	45,000	45,000	45,000	45,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issuance costs
-	-	-	-	-	-	-	-	-	192	192	192	192	0	0	0	0	-	-	-	-	-	-	-	-	261	0	0	0	-	-	-	-	-	-	-	-
Payment on termination of credit agreement with HealthCare Royalty Partners, III, L.P.
0	37,162	37,162	37,162	37,162	0	0	0	0	18,303	18,303	18,303	18,303	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of Debt
0	1,825	3,495	4,855	6,114	6,104	5,762	5,421	5,093	4,954	4,680	4,739	4,758	4,273	4,589	4,627	4,424	4,163	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-1,215	23,271	22,693	20,766	21,617	-5,961	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,409	5,334	4,754	2,080	0	0	0
Net decrease in cash and cash equivalents and restricted cash
-29,418	-7,390	-4,204	-3,246	18,030	-14,652	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property and equipment purchases in accounts payable
0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in)/provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0	-	6,696	17,329	20,145	20,000	0	0	0	-	-	-	-	-	-	-	-
Net (decrease)/increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	12,250	29,166	18,034	27,725	-7,053	-7,988	-22,842	-8,775	25,344	0	0	0	-	-	-	-1,811	-3,156	5,969	-2,346	-4,968	-2,372	-4,074	5,297	3,568	7,293	0	0	0
Property and equipment purchases in accounts payable
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivable for issuances of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental cash flow data:
Cash paid for interest
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash commitment shares issued to Aspire Capital
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid and accrued equity issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-